Latest Booster Innovation Fund (NZX:BIF) News

DGR Global led the week after a Takeovers Panel finding raised fresh questions about control and voting rights. Smaller companies also exposed fragile finances, while several funds remained suspended or faced large investment losses.

Booster has secured a further $7.4 million capital commitment for the Booster Innovation Fund, taking total committed and allocated capital above $23 million. The funding announcement arrives alongside disclosure of civil proceedings by New Zealand’s Financial Markets Authority and a new independent director.

Biotech funding and regulatory setbacks drove the week’s biggest healthcare share moves, while larger companies delivered stronger earnings and deal activity. Telix’s proposed ITM takeover, Ramsay’s demerger plans and a mixed group of clinical updates kept investors focused on cash, approvals and sales.

Booster Innovation Fund has invested $200,000 in TheiaNova, a University of Auckland spinout developing a self-administered eye drop for keratoconus. The seed-stage bet accounts for 0.76% of BIF’s portfolio, keeping the exposure modest while adding an early biotechnology asset.

Dealmaking and capital moves drove the week in financials, while one regulatory shock hit hard. PEXA slumped, but Magellan, Euroz Hartleys and several smaller finance names rose on mergers, asset sales and balance-sheet updates.

Booster Innovation Fund reported a $1.593 million profit for the year ended March 2026, supported by increased net assets. However, valuation risks persist due to early-stage investments and recent capital raises at lower prices.

ASX Ltd sank, while Klevo and Judo Bank surged as investors split sharply between costly regulatory problems and clearer growth plans. Payments, retirement income and capital management drove the busiest finance stories of the week.

Booster Innovation Fund has trimmed its net asset value per unit to $1.47 following a $723,000 valuation adjustment driven by slower growth and capital raising dynamics in its portfolio.